A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

This trial is comparing a new antibody-drug therapy (BL-M07D1) to the standard treatment (T-DM1) in women with HER2-positive breast cancer who had cancer remaining after their pre-surgery (neoadjuvant) treatment. **You may be eligible if...** - You are a woman aged 18–75 with confirmed HER2-positive invasive breast cancer - Your cancer stage before neoadjuvant therapy was T1–T4, N0–N3, M0 (excluding T1N0) - You still had invasive cancer in the breast or lymph nodes after your surgery - You completed a qualifying course of neoadjuvant chemotherapy plus anti-HER2 therapy - Your radical surgery was completed 3–12 weeks before starting the study drug - Your ECOG score is 0 or 1 and prior treatment side effects have mostly resolved **You may NOT be eligible if...** - You had a complete pathologic response (no cancer remaining) after surgery - You did not complete the required neoadjuvant therapy - You are pregnant, breastfeeding, or not using effective contraception - You received a blood transfusion or colony-stimulating factors within 14 days before the first dose Talk to your doctor to see if this trial is right for you.